Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Adducin α CRISPR/Cas9 KO Plasmid (h): sc-401693
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Adducin α CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Adducin α genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Adducin α Antibody (4D1): sc-33633
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Adducin α CRISPR/Cas9 KO Plasmid (h) | sc-401693 | 20 µg | $397.00 |
Overview
ADD1 encodes adducin α, a membrane skeletal protein that caps actin filaments and promotes spectrin–actin network assembly at the cell cortex. Through regulation of cytoskeletal remodeling, adducin α influences cell shape, adhesion, and membrane stability, with downstream effects on processes such as cell migration and mechanotransduction. Adducin function is modulated by phosphorylation-dependent signaling, including PKC- and PKA-linked pathways that alter actin-binding dynamics and cortical organization. Dysregulation of cytoskeletal and membrane scaffolding proteins, including ADD1, has been associated with altered epithelial barrier properties and cellular phenotypes relevant to cardiovascular and neurobiological research.
Adducin α CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADD1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADD1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADD1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Adducin α protein expression.
This CRISPR knockout system enables efficient generation of ADD1-deficient cell models for investigation of Adducin α signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ADD1 exon(s) critical for Adducin α function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ADD1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Adducin α CRISPR/Cas9 KO Plasmid (h) and Adducin α CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ADD1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Adducin α HDR Plasmid (h) and Adducin α HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ADD1 homology arms to support homology-directed repair at defined ADD1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.